Neisseria meningitidis Antigens/Antibodies

2024-07-08 444

Meningococcal disease, caused by the capsulated Gram-negative bacterium Neisseria meningitidis, is a communicable disease primarily transmitted through close contact or droplet aerosols, can rapidly progress and cause severe complications or death.

There are at least 12 identified N. meningitidis serogroups, including A, B, C, W, X, and Y. Current quadrivalent capsular polysaccharide-protein conjugate vaccines effectively prevent disease caused by four serogroups (A, C, Y, and W); however, these vaccines do not provide protection against serogroup B (MenB).

Given the recent outbreaks of meningococcal serogroup B (MenB) on school campuses, developing a vaccine for serogroup B is an urgent public health priority. vaccine development has been challenging due to the poor immunogenicity of polysaccharide-based vaccines. Consequently, vaccine development has shifted focus towards identifying outer membrane proteins that can elicit broad and protective immune responses. FHbp, NadA and NHBA are three promising MenB vaccine candidates.

Figure 1 Schematic representation of Neisseria meningitidis serogroup B (MenB)

AntibodySystem proudly introduces the top-tier viral antigen/antibody library, SAA Vir^®. This extensive collection includes over 1,000 rigorously tested products from more than 100 virus types/subtypes and 400 strains, with high-quality antigens expressed in eukaryotic cells. The SAA Vir^® line features a unique catalog of bacterial and viral antigens, including RSV, Flu, COVID-19, HPV, Hantavirus, Ebola, and DENV, along with proteins, antibodies, and related kits to meet the needs of scientific research and vaccine development.

All products are for research use only